相关实验视频

Updated: Mar 6, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

在Oligometastatic乳腺癌中局部废除疗法

Tori C Nierenberg¹, Samantha M Thomas^2,3, Ian Halliday¹

¹Department of Surgery, Duke University Medical Center, Durham, North Carolina.

|March 4, 2026

概括

针对新发转移性乳腺癌 (dnMBC) 的手术,使用单位寡转移,特别是初级乳腺瘤切除 (BR) 或与转移性部位治疗 (BR+MT) 结合,与改善整体存活率 (OS) 相关. 然而,仅仅对转移部位治疗 (MT) 显示了更糟糕的生存状况.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
乳腺癌研究研究乳腺癌研究

背景情况:

新发转移性乳腺癌 (dnMBC) 的管理通常优先考虑缓解,使手术或废除疗法的生存影响不清楚,特别是在寡头转移性疾病中.
由单位转移 (大脑,骨,肝脏或肺部) 定义的低基因转移性dnMBC,在地方干预可能影响结果的情况下,提出了一个独特的挑战.

研究的目的:

在被诊断为单位寡头转移性dnMBC的患者中,研究一次性和/或转移性部位的手术和/或局部消耗性治疗与整体存活率 (OS) 之间的关联.
为了比较没有接受局部废除疗法 (NLT) 的患者与仅接受初级乳腺瘤切除 (BR),仅进行转移部位废除疗法 (MT) 或两者 (BR+MT) 的患者的OS.

主要方法:

使用国家癌症数据库 (2010-2020年) 进行的一项回顾性队列研究确定了接受全身治疗的单位寡基质化dnMBC患者.
患者被分为四组:NLT,BR,MT和BR+MT. 后勤回归确定了与治疗策略相关的因素,多变量建模估计了治疗与OS的关联.
数据分析于2024年8月至2025年9月期间进行,重点关注整体生存率作为主要结果衡量标准.

主要成果:

该研究包括22,433名患者;仅骨转移最常见 (68.8%). 在少数病例中使用局部废除疗法 (BR+MT:6.4%,MT:10.6%,BR:15.3%).
高龄和更高的并发症得分与接受NLT相关.
与NLT相比,初级乳腺瘤切除 (BR) 和联合治疗 (BR+MT) 与改善的生存状况相关 (HR分别为0.62和0.60). 相反,仅仅转移部位治疗 (MT) 与更糟糕的生存状况有关 (HR 1.22).

结论:

很少有单位dnmBC患者接受手术或废除疗法,尽管有潜在的生存益处.
主要乳腺瘤切除,单独 (BR) 或与转移部位治疗 (BR+MT) 结合,与此患者群体的整体存活率有所改善有关.
对于被考虑进行侵入性干预的单位dnmBC患者,切除原发性乳腺瘤可能会提供生存优势.

更多相关视频

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Thermal Ablation for the Treatment of Abdominal Tumors

Thermal Ablation for the Treatment of Abdominal Tumors

Published on: March 7, 2011

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.